In this issue:
- BI 695501 biosimilar vs adalimumab in advanced CD
- Adalimumab biosimilar SB5 in IBD
- Etrolizumab for UC
- Etrolizumab as induction and maintenance therapy for UC (HICKORY)
- Etrolizumab for maintenance therapy in active UC (LAUREL)
- Etrolizumab vs infliximab for active UC (GARDENIA)
- Etrolizumab vs adalimumab or placebo as induction for UC (HIBISCUS I & II)
- Prediction of IBD course based on faecal volatile compounds
- Risk of dementia in patients with IBD
- Paradoxical psoriasis or psoriasiform lesions with anti-TNFs
- Patients’ and caregivers’ perspectives on biosimilar use in paediatric IBD
- Co-existent IBD and coeliac disease in children
- Science blog: Inflammation in colitis-associated cancer
Please login below to download this issue (PDF)